Australia Sickle Cell Disease Drug Market Report 2022 to 2030

Australia Sickle Cell Disease Drug Market Analysis

$ 3999$ 2999

Australia's Sickle Cell Disease Drug Market is expected to grow from $1.1 Mn in 2022 to $2.6 Mn in 2030 with a CAGR of 11% for the year 2022-2030. Immigration from other countries such as Africa and the Middle East etc along with newly licensed drugs for the treatment of sickle cell disease is driving the growth of the Australia Sickle Cell Disease Drug Market. the market is segmented by treatment modalities and by distribution channel. Some of the key players in the Australia Sickle Cell Disease Drug Market are Baxter Healthcare, Lipa Pharmaceutical, and Pfizer.

ID: IN10AUPH367 CATEGORY: Pharmaceuticals GEOGRAPHY: Australia AUTHOR: Parul Choudhary

Buy Now

Australia Sickle Cell Disease Drug Market Executive Analysis

Australia's sickle cell disease drug market size is at around $1.1 Mn in 2022 and is projected to reach $2.6 Mn in 2030, exhibiting a CAGR of 11% during the forecast period. In 2022–2023, total health spending in Australia is anticipated to rise by 3.3% to $238.1 Bn. Growth in health spending for the current year has been restrained by the reduction of COVID-19-related expenditures. An increase in Medicare costs, which mostly consist of Medicare and Private Health Insurance Rebate expenses, will, however, spur development in medical services and benefits. Along with this, the Australian Government's financial support for public hospitals is expected to increase as the demand for services rises. Australia's aging population has also continued to be a driving force for health services, which has led to an increase in health spending overall.

Sickle cell disease (SCD) and its variants are hereditary illnesses caused by a mutant form of hemoglobin called hemoglobin S. (HbS). Normal hemoglobin-containing red blood cells are smooth, disk-shaped, and malleable, like doughnuts without holes. They can readily pass through the blood vessels. Sickle cell hemoglobin-containing cells are rigid and sticky. When they run out of oxygen, they take the form of a sickle or a crescent, similar to the letter C. These cells adhere to one another and find it difficult to pass via blood arteries. This may restrict the flow of healthy, regular, oxygen-carrying blood through small blood vessels and this obstruction can be painful.

In comparison to other countries, Australia has a comparatively low incidence of sickle cell disease. Only 400 people in Australia are thought to have sickle cell disease, and most of them are immigrants or their descendants who came from nations where the condition is more common. Monash University's Public Health and Preventative Medicine department runs a program called the Haemoglobinopathy Registry (HbR) to gather information on the incidence of sickle cell disease in Australia. HbR is an Australian national registry for people who have blood disorders, including SCD. An organization called Australian Sickle Cell Advocacy Inc. (ASCA) works to protect the rights of Australians with sickle cell disease as they navigate the country's healthcare system. With pharmaceutical treatment being limited to one medicine in Australia, blood transfusion is one of the most effective therapeutic choices for this disease. For adults and children with sickle cell disease who are 16 years of age or older, crizanlizumab-tmca has been approved. The drug is injected into a vein via an intravenous line, aids in preventing blood cells from adhering to blood vessel walls, and results in blood flow blockage, inflammation, and painful episodes.

australia sickle cell disease drug market analysis

Market Dynamics

Market Growth Drivers

As the immigration of Hispanic Americans of Middle Eastern, Asian, Indian, Mediterranean, South American, and Central American origin rises, SCD prevalence will rise in Australia. With the introduction of some of the products licensed for the treatment of sickle cell disease, such as (Emmaus Life Sciences), the world is experiencing a major surge of innovation, which will eventually cause the Australia Sickle Cell Disease Drug Market to grow.

Market Restraints

Due to the high cost of treatment, sickle cell disease imposes a major financial burden on patients, health insurance companies, and government healthcare programs, limiting Australia's Sickle Cell Disease Drug Market growth. The market's potential is further restricted by the lack of Therapeutics Goods Administration (TGA) approved medications for the treatment of sickle cell disease.

Competitive Landscape

Key Players

Aspen (AUS)
Allergan (AUS)
Baxter Healthcare (AUS)
Lipa Pharmaceutical (AUS)
Pfizer
Sanofi
GlaxoSmithKline
Novartis
Johnson & Johnson

Healthcare Policies and Regulatory Landscape

Australia's citizens, permanent residents, and some expats have access to a variety of medical services and treatments including SCD through the government-funded healthcare system known as Medicare Australia. It covers a wide range of critical medical services, including doctor visits, specialist consultations, diagnostic procedures, and prescription medications. The Australian Department of Health is in charge of and finances Medicare. Although Medicare covers a significant portion of medical expenses, some services could have additional out-of-pocket charges or private health insurance requirements.

The Australian government's Pharmaceutical Benefits Scheme (PBS) program offers subsidized access to a variety of prescription drugs. It is a part of the broader Medicare system and was created to guarantee that Australians have cheap access to the pharmaceuticals they require.

The Australian government agency in charge of monitoring drugs, medical equipment, and other therapeutic products is known as the Therapeutic Goods Administration (TGA). The TGA is part of the Australian Department of Health and is in charge of evaluating pharmaceuticals for safety, quality, and efficacy before they are made accessible for use in Australia.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Sickle Cell Disease Drug Market Segmentation

By Treatment Modality

The pharmacotherapy segment is expected to grow tremendously in the forecasted period as limited treatment options are available in the market.

Bone Marrow Transplant
Blood Transfusion
Pharmacotherapy
Hydroxyurea
Branded Drugs
Endari
Adakeveo
Oxbryta
Zynteglo
CTX001
Mitapivat
FT-4202

By Distribution Channel

The hospital segment is expected to dominate the market throughout the forecast period.

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.